Lindis Blood Care develops CATUVAB®, a medical device that physically removes tumor cells from autologous blood without pharmacological, immunological, or metabolic action. The technology is intended to be integrated into existing clinical practice and positioned as a cost-effective alternative to allogeneic blood transfusions and their treatment-related costs. The company is preparing for regulatory approvals and commercialization, specifically pursuing CE Mark clearance in Europe and FDA marketing approval in the US. Lindis is based in Hennigsdorf, Germany, and was founded by Dr. Franzpeter Bracht and Dr. Horst Lindhofer. The company recently raised an undisclosed funding round to support those regulatory and market-launch activities. Investors in the round included Brandenburg Kapital (lead), High-Tech Gründerfonds, existing and new private investors, and the founders. Lindis Blood Care develops CATUVAB, a medical device that uses a trifunctional antibody and a filter to remove EpCAM-positive tumor cells from surgical blood to enable safe autotransfusion in cancer surgery. The company positions CATUVAB as a cost-effective, easily integrated alternative to allogeneic donor blood transfusions that could reduce severe side effects and tumor recurrence. Lindis reports proof of concept in vitro and in an initial clinical study, with treated surgical blood showing no detectable tumor cells. A confirmatory multicenter REMOVE study began in February 2021, and topline results were expected in mid-2022. The firm intends to use recent financing to expand the clinical program, complete CE marking procedures and start the FDA market application process. The clinical and regulatory milestones are intended to support partnering and market access efforts. Lindis Bloodcare develops CATUVAB, a medical-device solution that combines an antibody and a filter to reliably remove tumor cells from blood collected during surgery using the standard ATS method. The product is intended to enable self-blood administration of blood collected during operations and to be integrated into routine clinical practice as part of contemporary patient blood management. The company plans to use the newly raised funds for the clinical development of CATUVAB. Lindis Bloodcare received over €5m in total funding, including ILB grants under the ProFIT program of the European Regional Development Fund totaling €3.3m. Backers named in the report include High‑Tech Gründerfonds (HTGF), Brandenburg Kapital and five private investors. The company was co-founded by Horst Lindhofer and Franzpeter Bracht and is based in Hennigsdorf, Germany.

Total raised

$6M

Funding rounds

3

Latest round

Equity

Latest activity

Dec 2019